Together, our results revealed that neddylation inhibition induces apoptosis through p53 and p62 in VSMCs and improves neointimal hyperplasia mainly by promoting apoptosis through smooth muscle ...

Tissue remodeling depends on mesenchymal cells (fibroblasts and myofibroblasts) and is a prominent feature of chronic renal-transplant rejection. It is not known whether the mesenchymal cells that ...

Early in vivo studies in mice suggest sulindac, a nonsteroidal anti-inflammatory drug already used to induce regression of colon polyps, may prevent neointimal proliferation after arterial injury ...

Background: Neointimal hyperplasia of vascular smooth muscle cells (VSMCs) is caused by increased proliferation and decreased apoptosis. We previously reported that alpha-lipoic acid (ALA), a ...

Conclusions As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.

At 6 months, less neointimal hyperplasia was found at both the proximal and distal anastomoses. This included the prosthetic wall, suture region, and arterial wall.

OCT documented that the patients receiving the COMBO stent achieved neointimal regression from 9 months to 24 months. A reduction of in-stent percentage neointimal volume, which Lee said is “the most ...

In the EGO-COMBO study, a dual-therapy endothelial progenitor cell-capturing sirolimus-eluting stent achieved exceptional late neointimal regression, rendering favorable 36-month clinical results ...